Teleflex Incorporated · NYSE:TFX
Teleflex — Investor Day (November 2025)
19 slides from Teleflex's investor day presentation, Nov 14, 2025
Slide 1: Vascular Intervention Investor Call
Teleflex Incorporated Vascular Intervention Investor Call November 14, 2025
Slide 2: Conference Call Logistics
Conference Call Logistics The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors) An audio replay of the call will be available beginning at 11:00 am Eastern Time on November 14, 2025 either on the Teleflex website or by telephone. The call
Slide 3: Today's Speakers
Today’s Speakers Liam Kelly Matthew James Dr. Thierry Glauser Chairman, President, Global VP R&D Vascular President and CEO Interventional Access Intervention Dr. Chris Buller, MD Dr. Kevin Croce, MD Dr. Elliot Smith, MD Medical Director, Interventional Cardiologist Interventional Cardiologist Telef
Slide 4: Note on Forward-Looking Statements
Note on Forward-Looking Statements This presentation and our discussion contain forward-looking information and statements, which inherently involve risks and uncertainties that could cause actual results to differ from those projected or implied in the forward–looking statements. These statements i
Slide 5: Agenda
Agenda VI Growth Drivers Matt James, President of Teleflex Global Interventional Access Key technology & Matt James, President of Teleflex Global differentiators Interventional Access Thierry Glauser, Teleflex Vice President of R&D Future Pipeline for EMEA Vascular and Interventional Dr. Chris Bulle
Slide 6: VI is ready to contribute to sustainable revenue growth
VI is ready to contribute to sustainable revenue growth Underlying organic 2 Expansion of market Differentiated Strong customer 1 market growth & account access 3 4 engagement & education Portfolio Solid mid to high single-digit Uniting sales teams drives Unique portfolio to serve Building trust & m
Slide 7: Underlying organic market growth
1 Underlying organic market growth Ischemic heart disease (IHD) is the leading cause of global mortality1 510M Global prevalence of chronic heart disease (CHD) by Continued growth of cardiovascular interventions 20502 Increased age-related disease complexity. People >70 years account for a Chronic d
Slide 8: Expansion of market & account access
2 Expansion of market & account access Uniting sales teams drives presence & penetration. Upside potential from globalization of technology Focus on emerging, higher growth markets Stakeholder coverage DES & core MS% NA Economic relevance Economic relevance Roll-out Freesolve, NPDs BIOMAG-III IDE Fo
Slide 9: CVI Therapy Solutions
3 CVI Therapy Solutions Empowering physician choice from everyday to complex procedures Navigate Treat Rescue When seconds count Any level of complexity All lesions, whatever the strategy – “Leading the way in PCI” with confidence Guide Extension Microcatheters Pantera Lux® FreesolveTM Orsiro Missio
Slide 10: Broad & Differentiated VI Portfolio positioned in growing markets
Broad & Differentiated VI Portfolio positioned in growing markets Market value & Key Segments Representative Products growth* Coronary Vascular Intervention (CVI) $6.4Bn Orsiro™ Mission PK Papyrus™ Covered Pantera™ Lux™ Drug- Freesolve™ Drug-Eluting Stent Coronary Stent*** Coated Balloon (DCB) Resor
Slide 11: Why Resorbable Scaffolds?
Why Resorbable Scaffolds? Reduce long-term events of DES and acute limitations of DCB Reduced late clinical events compared to permanent stent implants: • Low thrombogenicity and events of scaffold thrombosis • No permanent implant (CT and MRI compatibility) Immediate & sustained vessel support duri
Slide 12: Strong customer engagement & education
4 Strong customer engagement & education Putting the customer at the center of everything we do Investing in health Advancing science Promoting peer Providing insights & care professional (HCP) through evidence exchange & consensus direction education generation 12
Slide 13: VI R&D pipeline will generate expansion into new, high growth segments
VI R&D pipeline will generate expansion into new, high growth segments Add-on market value Key Segments Near term Longer term & growth* -2033 Orsiro MissionTM Orsiro MissionTM Pantera™ Lux™ $1.0Bn Coronary VI Evolution (EVO) EVO Phase 2 DCB** Phase 1 New Generation AkoyaTM PK Papyrus™ Covered Stent*
Slide 14: Physician interview
Physician interview Dr. Chris Buller, MD Dr. Kevin Croce, MD Dr. Elliot Smith, MD Medical Director, Interventional Cardiologist Interventional Cardiologist Teleflex Brigham and Women’s Hospital Barts Heart Center Boston, MA London, UK
Slide 15: Vascular Intervention Business At A Glance
Vascular Intervention Business At A Glance Total Addressable Market of the Vascular 2024 Sales Mix of the Vascular Intervention Business Intervention Business2 Global Coronary Vascular Intervention Market Split By Sales Region Split By Product Area 64% EMEA PVI 53% 26% TAM: $10bn1 CVI AMERICAS 73% V
Slide 16: Executive Summary
Executive Summary – Vascular Intervention acquisition significantly expands Teleflex’s market presence with a combined Expanding Into An coronary/peripheral Interventional business Attractive Market – The peripheral intervention market is growing rapidly with global market growth estimated to be in
Slide 17: Thank You!
Thank You! Not all products are available in all countries. *Freesolve™ RMS is available in CE-mark accepting countries; Freesolve™ RMS is limited by US law to investigational use only. **PK Papyrus Covered Coronary Stent is a Humanitarian Device. Authorized by Federal law for use in the treatment o
Slide 18: Appendix
: Appendix Teleflex’ Empowering the future of healtheare
Slide 19: References
References 1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM et al. . Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol 2020;76:2982–3021. 2. Eur Heart J Qual Care Clin Outcomes, Volume 11, Issue 4, June 2025